title: Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression.
abstract: OBJECTIVE
  TSH suppression therapy in patients with differentiated thyroid cancer (DTC) has been associated with adverse effects on areal bone mineral density (aBMD) only in postmenopausal women. The purpose of study was to examine the effect of TSH suppression therapy on skeletal integrity using peripheral quantitative computed tomography (pQCT) at the radius and tibia in pre- and postmenopausal women with DTC and controls.
  
  
  METHODS
  Subjects included 80 women with DTC (40 pre- and 40 postmenopausal) and 89 (29 and 60, respectively) controls. pQCT was performed at the radius and tibia, Dual-energy X-ray absorptiometry (DXA) at the hip and lumbar spine, while samples were taken for calciotropic hormones and bone markers.
  
  
  RESULTS
  No differences were observed concerning aBMD by DXA. In premenopausal women, there were no significant differences concerning vBMD, while cortical thickness was higher at the radius in patients with DTC (P < 0·01) compared with controls. In postmenopausal women with DTC trabecular bone mineral content (BMC), area and vBMD were lower at the radius (all P < 0·05), while at the tibia trabecular BMC and vBMD were lower at the mixed transition zone (14% from the distal end, P < 0·05) compared with controls. Cortical thickness was lower at the radius (P < 0·01) in postmenopausal patients compared with controls. Serum CTX was higher in postmenopausal women with DCT (P < 0·01), while in premenopausal patients, parathyroid hormone (PTH) was lower (P = 0·01) compared with controls.
  
  
  CONCLUSIONS
  TSH suppression therapy is associated with higher bone resorption only in postmenopausal women; this adversely affects trabecular and cortical bone properties especially at nonweight-bearing sites such as the radius.
authors.affiliation: Laboratory of Research of Musculoskeletal System "Th. Garofalidis", Medical School, University of Athens, KAT Hospital, Athens, Greece.
authors.forename: Symeon
authors.initials: S
authors.lastname: Tournis
authors.forename: Julia D
authors.initials: JD
authors.lastname: Antoniou
authors.forename: Chrysoula G
authors.initials: CG
authors.lastname: Liakou
authors.forename: John
authors.initials: J
authors.lastname: Christodoulou
authors.forename: Evangellia
authors.initials: E
authors.lastname: Papakitsou
authors.forename: Antonios
authors.initials: A
authors.lastname: Galanos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Makris
authors.forename: Helen
authors.initials: H
authors.lastname: Marketos
authors.forename: Stamatina
authors.initials: S
authors.lastname: Nikopoulou
authors.forename: Ioanna
authors.initials: I
authors.lastname: Tzavara
authors.forename: Ioannis K
authors.initials: IK
authors.lastname: Triantafyllopoulos
authors.forename: Ismene
authors.initials: I
authors.lastname: Dontas
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papaioannou
authors.forename: Georgios P
authors.initials: GP
authors.lastname: Lyritis
authors.forename: Maria
authors.initials: M
authors.lastname: Alevizaki
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*; D016022:Case-Control Studies; D054893:Cone-Beam Computed Tomography; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D009929:Organ Size; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D013972:Thyrotropin / Q000037:antagonists & inhibitors; D013974:Thyroxine / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D013972:Thyrotropin; D013974:Thyroxine